Atea Pharmaceuticals, Inc.
Nasdaq AVIR · Boston, MA
Works in GI & liver · Infectious disease · Renal & urogenital · Respiratory · Women's health
Atea Pharmaceuticals, Inc. is a clinical trial sponsor based in Boston, MA, listed as Nasdaq AVIR. It has 4 active clinical trials with 1,854 planned participants, across 5 therapeutic areas. Since 2021 it has completed 23 trials and stopped 4 early.
Trial track record · since 2021
Financials · Nasdaq AVIR
Pipeline · 4 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Atea Pharmaceuticals, Inc
Atea Pharmaceuticals, Inc is lead sponsor of 4 active clinical trials on ClinicalTrials.gov, with 1,854 planned participants, in GI & liver, Infectious disease, Renal & urogenital, Respiratory and other areas. Since 2021 it has completed 23 trials and stopped 4 early.
Atea Pharmaceuticals, Inc is based in Boston, MA and is listed as Nasdaq AVIR. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Atea Pharmaceuticals, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-07-31.
Approve Suite is not affiliated with Atea Pharmaceuticals, Inc.. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.